Investments
14Funds
1About HEDA Ventures
HEDA Ventures is an early stage venture capital firm that focuses on high-tech innovation areas, hence promoting industry upgrading and optimization of HEDA, creating an entrepreneur-friendly environment, and building a comprehensive service platform for high-tech start-ups in the zone. The company is also the strategy investment platform of the Group. HEDA Ventures is based in Silicon Valley and Hangzhou, China.
HEDA Ventures Headquarter Location
19 Davis Drive Suite 203
Belmont, California, 94004,
United States
Latest HEDA Ventures News
Sep 13, 2017
Haywards-based Paragon Genomics, a developer of next generation sequencing (NGS) technology, has raised $8M in a Series A funding. The funding was led by Cowin Venture Capital and Fosun Industrial Co., Limited, and also included Cloudstone Venture, HEDA Ventures, and Wisemont Capital…. Try Some Advice From 80,000 Hours People in the tech world like to talk about doing great things. But what does that actually mean for your career? If you’re serious about making a pos... Square’s Board Adds Former Brown University President Ruth Simmons Square announced a powerful addition to its board today — former Brown University President Ruth Simmons. Before her 11-year post at Brown, she was th... TapHeaven Promises True Automation For Mobile Advertisers The pitch for TapHeaven might sound a little familiar. Co-founder and CEO Chris Hoyt said his technology delivers truly automated ad-buying.What makes... Share this entry
HEDA Ventures Investments
14 Investments
HEDA Ventures has made 14 investments. Their latest investment was in Chance Pharmaceuticals as part of their Series C on October 10, 2021.
HEDA Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
10/11/2021 | Series C | Chance Pharmaceuticals | $30M | Yes | 3 | |
10/11/2021 | Series C | Pulmed Pharma | $31M | Yes | China Merchants Securities Asset Management, Guozhong Venture Capital Management, and Lapam Capital | 7 |
8/27/2021 | Series B | Lynk Pharmaceuticals | $50M | Yes | 26 | |
4/16/2021 | Series B | |||||
12/8/2020 | Series D |
Date | 10/11/2021 | 10/11/2021 | 8/27/2021 | 4/16/2021 | 12/8/2020 |
|---|---|---|---|---|---|
Round | Series C | Series C | Series B | Series B | Series D |
Company | Chance Pharmaceuticals | Pulmed Pharma | Lynk Pharmaceuticals | ||
Amount | $30M | $31M | $50M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | China Merchants Securities Asset Management, Guozhong Venture Capital Management, and Lapam Capital | ||||
Sources | 3 | 7 | 26 |
HEDA Ventures Fund History
1 Fund History
HEDA Ventures has 1 fund, including Hangzhou Econ & Tech Dev Venture Capital Guidance Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
Hangzhou Econ & Tech Dev Venture Capital Guidance Fund | Fund Of Funds | Open | 1 |
Closing Date | |
|---|---|
Fund | Hangzhou Econ & Tech Dev Venture Capital Guidance Fund |
Fund Type | Fund Of Funds |
Status | Open |
Amount | |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.